Chemotherapy-Induced Nausea and Vomiting Market

The chemotherapy-induced nausea and vomiting market has been comprehensively analyzed in IMARC's new report titled "Chemotherapy-Induced Nausea and Vomiting Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Chemotherapy-induced nausea and vomiting (CINV) refers to a significant and distressing side effect experienced by patients undergoing chemotherapy treatments for cancer. It is mainly characterized by a sense of unease in the stomach and the involuntary urge to vomit, which can occur immediately after chemotherapy (acute onset) or can be delayed, appearing days after the treatment. The indications of this condition range from mild nausea to severe vomiting, potentially leading to dehydration, electrolyte imbalances, and a decline in the patient's quality of life. The risk and severity of CINV vary depending on the type of chemotherapy, the dose, the treatment duration, and individual patient factors such as age, gender, and previous experience with nausea and vomiting. Diagnosis of CINV primarily involves clinical evaluation, where healthcare professionals assess the patient's symptoms, chemotherapy regimen, and medical history.

The escalating prevalence of cancer, coupled with the growing demand for chemotherapeutic agents that trigger the chemoreceptor trigger zone and vomiting center in the brain, is primarily driving the chemotherapy-induced nausea and vomiting market. In addition to this, the inflating utilization of newer, more effective antiemetic medications, such as serotonin (5-HT3) receptor antagonists, neurokinin-1 (NK1) receptor antagonists, and corticosteroids, to prevent and control nausea and vomiting, is creating a positive outlook for the market. Moreover, the widespread adoption of combination therapy, which involves using multiple antiemetics targeting different pathways of the nausea and vomiting reflex, is also bolstering the market growth. Apart from this, the rising usage of personalized treatment regimens tailored to specific chemotherapy and individual patient risk factors is acting as another significant growth-inducing factor. Additionally, the increasing focus on patient-centered care and the continuous advancement in chemotherapy protocols is further propelling the market growth. Besides this, the emerging popularity of non-pharmacological interventions, such as acupuncture, acupressure, and relaxation techniques, which complement pharmacological treatments in managing the condition, is expected to drive the chemotherapy-induced nausea and vomiting market during the forecast period.

IMARC Group's new report provides an exhaustive analysis of the chemotherapy-induced nausea and vomiting market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for chemotherapy-induced nausea and vomiting and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the chemotherapy-induced nausea and vomiting market in any manner.

Time Period of the Study

• Base Year: 2023
• Historical Period: 2018-2023
• Market Forecast: 2024-2034
   

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan
   

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the chemotherapy-induced nausea and vomiting market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the chemotherapy-induced nausea and vomiting market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape

This report also provides a detailed analysis of the current chemotherapy-induced nausea and vomiting marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report

Key Questions Answered in this Report

Market Insights

• How has the chemotherapy-induced nausea and vomiting market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
• What was the country-wise size of the chemotherapy-induced nausea and vomiting market across the seven major markets in 2023 and what will it look like in 2034?
• What is the growth rate of the chemotherapy-induced nausea and vomiting market across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?
   

Epidemiology Insights

• What is the number of prevalent cases (2018-2034) of chemotherapy-induced nausea and vomiting across the seven major markets?
• What is the number of prevalent cases (2018-2034) of chemotherapy-induced nausea and vomiting by age across the seven major markets?
• What is the number of prevalent cases (2018-2034) of chemotherapy-induced nausea and vomiting by gender across the seven major markets?
• How many patients are diagnosed (2018-2034) with chemotherapy-induced nausea and vomiting across the seven major markets?
• What is the size of the chemotherapy-induced nausea and vomiting patient pool (2018-2023) across the seven major markets?
• What would be the forecasted patient pool (2024-2034) across the seven major markets?
• What are the key factors driving the epidemiological trend of chemotherapy-induced nausea and vomiting?
• What will be the growth rate of patients across the seven major markets?
   

Chemotherapy-Induced Nausea and Vomiting: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for chemotherapy-induced nausea and vomiting drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the chemotherapy-induced nausea and vomiting market?
• What are the key regulatory events related to the chemotherapy-induced nausea and vomiting market?
• What is the structure of clinical trial landscape by status related to the chemotherapy-induced nausea and vomiting market?
• What is the structure of clinical trial landscape by phase related to the chemotherapy-induced nausea and vomiting market?
• What is the structure of clinical trial landscape by route of administration related to the chemotherapy-induced nausea and vomiting market?